View ValuationVaxxa 将来の成長Future 基準チェック /06現在、 Vaxxaの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Entertainment 収益成長17.4%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesBoard Change • May 20No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. No independent directors (4 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.お知らせ • Mar 24Vaxxa AB to Report Q1, 2026 Results on Apr 22, 2026Vaxxa AB announced that they will report Q1, 2026 results on Apr 22, 2026お知らせ • Sep 24Vaxxa AB to Report Q3, 2025 Results on Oct 23, 2025Vaxxa AB announced that they will report Q3, 2025 results on Oct 23, 2025お知らせ • Jun 18Vaxxa AB to Report Q2, 2025 Results on Jul 17, 2025Vaxxa AB announced that they will report Q2, 2025 results on Jul 17, 2025お知らせ • Mar 25Vaxxa AB to Report Q1, 2025 Results on Apr 23, 2025Vaxxa AB announced that they will report Q1, 2025 results on Apr 23, 2025お知らせ • Jan 22Vaxxa AB to Report Fiscal Year 2024 Results on Feb 20, 2025Vaxxa AB announced that they will report fiscal year 2024 results on Feb 20, 2025Reported Earnings • Oct 17Third quarter 2024 earnings released: EPS: kr0 (vs kr0.035 loss in 3Q 2023)Third quarter 2024 results: EPS: kr0 (improved from kr0.035 loss in 3Q 2023). Revenue: kr22.4m (up 125% from 3Q 2023). Net income: kr7.0k (up kr806.0k from 3Q 2023). Profit margin: 0% (up from net loss in 3Q 2023). The move to profitability was driven by higher revenue.New Risk • Sep 16New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (29% average weekly change). Shareholders have been substantially diluted in the past year (over 17x increase in shares outstanding). Market cap is less than US$10m (€5.14m market cap, or US$5.72m).New Risk • Jul 21New major risk - Revenue and earnings growthEarnings have declined by 31% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (29% average weekly change). Earnings have declined by 31% per year over the past 5 years. Shareholders have been substantially diluted in the past year (over 17x increase in shares outstanding). Market cap is less than US$10m (€3.53m market cap, or US$3.83m).Reported Earnings • Jul 18Second quarter 2024 earnings released: EPS: kr0.02 (vs kr0.87 loss in 2Q 2023)Second quarter 2024 results: EPS: kr0.02 (up from kr0.87 loss in 2Q 2023). Revenue: kr22.5m (up 123% from 2Q 2023). Net income: kr671.0k (up kr2.22m from 2Q 2023). Profit margin: 3.0% (up from net loss in 2Q 2023). The move to profitability was driven by higher revenue.お知らせ • Jun 18Vaxxa AB to Report Q2, 2024 Results on Jul 17, 2024Vaxxa AB announced that they will report Q2, 2024 results on Jul 17, 2024Reported Earnings • Apr 10First quarter 2024 earnings released: EPS: kr0.012 (vs kr1.00 loss in 1Q 2023)First quarter 2024 results: EPS: kr0.012 (up from kr1.00 loss in 1Q 2023). Revenue: kr21.1m (up 245% from 1Q 2023). Net income: kr312.0k (up kr2.97m from 1Q 2023). Profit margin: 1.5% (up from net loss in 1Q 2023). The move to profitability was driven by higher revenue.お知らせ • Apr 04Vaxxa AB to Report Q1, 2024 Results on May 03, 2024Vaxxa AB announced that they will report Q1, 2024 results on May 03, 2024お知らせ • Mar 26Vaxxa AB, Annual General Meeting, Apr 24, 2024Vaxxa AB, Annual General Meeting, Apr 24, 2024.New Risk • Mar 15New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Over 12x increase in shares outstanding. This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr2.4m free cash flow). Share price has been highly volatile over the past 3 months (56% average daily change). Earnings have declined by 48% per year over the past 5 years. Shareholders have been substantially diluted in the past year (over 12x increase in shares outstanding). Market cap is less than US$10m (€1.94m market cap, or US$2.11m).Reported Earnings • Feb 26Full year 2023 earnings released: kr0.002 loss per share (vs kr0.28 loss in FY 2022)Full year 2023 results: kr0.002 loss per share (improved from kr0.28 loss in FY 2022). Revenue: kr55.6m (up 22% from FY 2022). Net loss: kr5.10m (loss narrowed 90% from FY 2022).New Risk • Feb 16New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Over 12x increase in shares outstanding. This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr26m free cash flow). Share price has been highly volatile over the past 3 months (100% average weekly change). Earnings have declined by 56% per year over the past 5 years. Shareholders have been substantially diluted in the past year (over 12x increase in shares outstanding). Market cap is less than US$10m (€2.11m market cap, or US$2.28m). Minor Risk Revenue is less than US$5m (kr41m revenue, or US$3.9m).お知らせ • Feb 07Vaxxa AB to Report Q3, 2024 Results on Mar 01, 2024Vaxxa AB announced that they will report Q3, 2024 results on Mar 01, 2024お知らせ • Jan 25Vaxxa AB to Report Fiscal Year 2023 Results on Feb 23, 2024Vaxxa AB announced that they will report fiscal year 2023 results on Feb 23, 2024お知らせ • Sep 28Vaxxa AB to Report Q3, 2023 Results on Oct 27, 2023Vaxxa AB announced that they will report Q3, 2023 results on Oct 27, 2023Reported Earnings • Aug 28Second quarter 2023 earnings released: kr0.01 loss per share (vs kr0.02 loss in 2Q 2022)Second quarter 2023 results: kr0.01 loss per share (improved from kr0.02 loss in 2Q 2022). Revenue: kr10.7m (down 19% from 2Q 2022). Net loss: kr1.55m (loss narrowed 61% from 2Q 2022).お知らせ • Jul 26Vaxxa AB to Report Q2, 2023 Results on Aug 24, 2023Vaxxa AB announced that they will report Q2, 2023 results on Aug 24, 2023お知らせ • May 22Augeo Group AB, Annual General Meeting, Jun 20, 2023Augeo Group AB, Annual General Meeting, Jun 20, 2023.Reported Earnings • May 22First quarter 2023 earnings releasedFirst quarter 2023 results: Revenue: kr6.42m (up 30% from 1Q 2022). Net loss: kr2.65m (loss narrowed 12% from 1Q 2022).Reported Earnings • Feb 22Full year 2022 earnings released: kr0.28 loss per share (vs kr0.20 loss in FY 2021)Full year 2022 results: kr0.28 loss per share (further deteriorated from kr0.20 loss in FY 2021). Revenue: kr46.9m (up kr45.5m from FY 2021). Net loss: kr51.1m (loss widened 303% from FY 2021).お知らせ • Jan 23Augeo Group AB to Report Fiscal Year 2022 Results on Feb 21, 2023Augeo Group AB announced that they will report fiscal year 2022 results on Feb 21, 2023Board Change • Nov 16No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Reported Earnings • Nov 02Third quarter 2022 earnings releasedThird quarter 2022 results: Revenue: kr12.7m (up kr11.5m from 3Q 2021). Net loss: kr6.71m (loss widened 308% from 3Q 2021).Reported Earnings • Aug 25Second quarter 2022 earnings releasedSecond quarter 2022 results: Revenue: kr13.4m (up kr12.3m from 2Q 2021). Net loss: kr3.94m (loss widened 80% from 2Q 2021).Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.お知らせ • Apr 04ESEN eSports AB, Annual General Meeting, May 02, 2022ESEN eSports AB, Annual General Meeting, May 02, 2022.Reported Earnings • Oct 31Third quarter 2021 earnings releasedThe company reported a solid third quarter result with reduced losses, improved revenues and improved control over expenses. Third quarter 2021 results: Revenue: kr1.20m (up 459% from 3Q 2020). Net loss: kr1.82m (loss narrowed 18% from 3Q 2020). このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Vaxxa は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測DB:7WA0 - アナリストの将来予測と過去の財務データ ( )SEK Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数3/31/202683-10N/AN/AN/A12/31/202577-9N/AN/AN/A9/30/202568-3-10N/A6/30/202569-3-2-2N/A3/31/202576-1N/AN/AN/A12/31/2024840N/AN/AN/A9/30/2024920N/AN/AN/A6/30/202480-1N/AN/AN/A3/31/202468-2N/AN/AN/A12/31/202354-5N/AN/AN/A9/30/2023-4-32N/AN/AN/A6/30/2023-2-38-26-5N/A3/31/20231-42N/AN/AN/A12/31/2022N/A-42-23-2N/A9/30/202232-22N/AN/AN/A6/30/202221-17-5-5N/A3/31/20229-14N/AN/AN/A12/31/20215-13-7-7N/A9/30/20214-7N/AN/AN/A6/30/20213-8-7-7N/A3/31/20211-7N/AN/AN/A12/31/20201-6-5-4N/A9/30/20201-5-2-2N/A6/30/20201-4-3-3N/A3/31/20201-5N/AN/AN/A12/31/20191-5N/A-6N/A9/30/20191-6N/A-7N/A6/30/20192-5N/A-6N/A3/31/20192-5N/AN/AN/A12/31/20183-4N/A-3N/A9/30/20183-4N/A-1N/A6/30/20184-4N/AN/AN/A3/31/20184-4N/AN/AN/A12/31/20174-4N/A-5N/A9/30/20174-3N/AN/AN/A12/31/20161-1N/A-1N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: 7WA0の予測収益成長が 貯蓄率 ( 1.9% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: 7WA0の収益がGerman市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: 7WA0の収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: 7WA0の収益がGerman市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: 7WA0の収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: 7WA0の 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YMedia 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/24 13:39終値2026/05/22 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Vaxxa AB 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
Board Change • May 20No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. No independent directors (4 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
お知らせ • Mar 24Vaxxa AB to Report Q1, 2026 Results on Apr 22, 2026Vaxxa AB announced that they will report Q1, 2026 results on Apr 22, 2026
お知らせ • Sep 24Vaxxa AB to Report Q3, 2025 Results on Oct 23, 2025Vaxxa AB announced that they will report Q3, 2025 results on Oct 23, 2025
お知らせ • Jun 18Vaxxa AB to Report Q2, 2025 Results on Jul 17, 2025Vaxxa AB announced that they will report Q2, 2025 results on Jul 17, 2025
お知らせ • Mar 25Vaxxa AB to Report Q1, 2025 Results on Apr 23, 2025Vaxxa AB announced that they will report Q1, 2025 results on Apr 23, 2025
お知らせ • Jan 22Vaxxa AB to Report Fiscal Year 2024 Results on Feb 20, 2025Vaxxa AB announced that they will report fiscal year 2024 results on Feb 20, 2025
Reported Earnings • Oct 17Third quarter 2024 earnings released: EPS: kr0 (vs kr0.035 loss in 3Q 2023)Third quarter 2024 results: EPS: kr0 (improved from kr0.035 loss in 3Q 2023). Revenue: kr22.4m (up 125% from 3Q 2023). Net income: kr7.0k (up kr806.0k from 3Q 2023). Profit margin: 0% (up from net loss in 3Q 2023). The move to profitability was driven by higher revenue.
New Risk • Sep 16New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (29% average weekly change). Shareholders have been substantially diluted in the past year (over 17x increase in shares outstanding). Market cap is less than US$10m (€5.14m market cap, or US$5.72m).
New Risk • Jul 21New major risk - Revenue and earnings growthEarnings have declined by 31% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (29% average weekly change). Earnings have declined by 31% per year over the past 5 years. Shareholders have been substantially diluted in the past year (over 17x increase in shares outstanding). Market cap is less than US$10m (€3.53m market cap, or US$3.83m).
Reported Earnings • Jul 18Second quarter 2024 earnings released: EPS: kr0.02 (vs kr0.87 loss in 2Q 2023)Second quarter 2024 results: EPS: kr0.02 (up from kr0.87 loss in 2Q 2023). Revenue: kr22.5m (up 123% from 2Q 2023). Net income: kr671.0k (up kr2.22m from 2Q 2023). Profit margin: 3.0% (up from net loss in 2Q 2023). The move to profitability was driven by higher revenue.
お知らせ • Jun 18Vaxxa AB to Report Q2, 2024 Results on Jul 17, 2024Vaxxa AB announced that they will report Q2, 2024 results on Jul 17, 2024
Reported Earnings • Apr 10First quarter 2024 earnings released: EPS: kr0.012 (vs kr1.00 loss in 1Q 2023)First quarter 2024 results: EPS: kr0.012 (up from kr1.00 loss in 1Q 2023). Revenue: kr21.1m (up 245% from 1Q 2023). Net income: kr312.0k (up kr2.97m from 1Q 2023). Profit margin: 1.5% (up from net loss in 1Q 2023). The move to profitability was driven by higher revenue.
お知らせ • Apr 04Vaxxa AB to Report Q1, 2024 Results on May 03, 2024Vaxxa AB announced that they will report Q1, 2024 results on May 03, 2024
お知らせ • Mar 26Vaxxa AB, Annual General Meeting, Apr 24, 2024Vaxxa AB, Annual General Meeting, Apr 24, 2024.
New Risk • Mar 15New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Over 12x increase in shares outstanding. This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr2.4m free cash flow). Share price has been highly volatile over the past 3 months (56% average daily change). Earnings have declined by 48% per year over the past 5 years. Shareholders have been substantially diluted in the past year (over 12x increase in shares outstanding). Market cap is less than US$10m (€1.94m market cap, or US$2.11m).
Reported Earnings • Feb 26Full year 2023 earnings released: kr0.002 loss per share (vs kr0.28 loss in FY 2022)Full year 2023 results: kr0.002 loss per share (improved from kr0.28 loss in FY 2022). Revenue: kr55.6m (up 22% from FY 2022). Net loss: kr5.10m (loss narrowed 90% from FY 2022).
New Risk • Feb 16New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Over 12x increase in shares outstanding. This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr26m free cash flow). Share price has been highly volatile over the past 3 months (100% average weekly change). Earnings have declined by 56% per year over the past 5 years. Shareholders have been substantially diluted in the past year (over 12x increase in shares outstanding). Market cap is less than US$10m (€2.11m market cap, or US$2.28m). Minor Risk Revenue is less than US$5m (kr41m revenue, or US$3.9m).
お知らせ • Feb 07Vaxxa AB to Report Q3, 2024 Results on Mar 01, 2024Vaxxa AB announced that they will report Q3, 2024 results on Mar 01, 2024
お知らせ • Jan 25Vaxxa AB to Report Fiscal Year 2023 Results on Feb 23, 2024Vaxxa AB announced that they will report fiscal year 2023 results on Feb 23, 2024
お知らせ • Sep 28Vaxxa AB to Report Q3, 2023 Results on Oct 27, 2023Vaxxa AB announced that they will report Q3, 2023 results on Oct 27, 2023
Reported Earnings • Aug 28Second quarter 2023 earnings released: kr0.01 loss per share (vs kr0.02 loss in 2Q 2022)Second quarter 2023 results: kr0.01 loss per share (improved from kr0.02 loss in 2Q 2022). Revenue: kr10.7m (down 19% from 2Q 2022). Net loss: kr1.55m (loss narrowed 61% from 2Q 2022).
お知らせ • Jul 26Vaxxa AB to Report Q2, 2023 Results on Aug 24, 2023Vaxxa AB announced that they will report Q2, 2023 results on Aug 24, 2023
お知らせ • May 22Augeo Group AB, Annual General Meeting, Jun 20, 2023Augeo Group AB, Annual General Meeting, Jun 20, 2023.
Reported Earnings • May 22First quarter 2023 earnings releasedFirst quarter 2023 results: Revenue: kr6.42m (up 30% from 1Q 2022). Net loss: kr2.65m (loss narrowed 12% from 1Q 2022).
Reported Earnings • Feb 22Full year 2022 earnings released: kr0.28 loss per share (vs kr0.20 loss in FY 2021)Full year 2022 results: kr0.28 loss per share (further deteriorated from kr0.20 loss in FY 2021). Revenue: kr46.9m (up kr45.5m from FY 2021). Net loss: kr51.1m (loss widened 303% from FY 2021).
お知らせ • Jan 23Augeo Group AB to Report Fiscal Year 2022 Results on Feb 21, 2023Augeo Group AB announced that they will report fiscal year 2022 results on Feb 21, 2023
Board Change • Nov 16No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Reported Earnings • Nov 02Third quarter 2022 earnings releasedThird quarter 2022 results: Revenue: kr12.7m (up kr11.5m from 3Q 2021). Net loss: kr6.71m (loss widened 308% from 3Q 2021).
Reported Earnings • Aug 25Second quarter 2022 earnings releasedSecond quarter 2022 results: Revenue: kr13.4m (up kr12.3m from 2Q 2021). Net loss: kr3.94m (loss widened 80% from 2Q 2021).
Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
お知らせ • Apr 04ESEN eSports AB, Annual General Meeting, May 02, 2022ESEN eSports AB, Annual General Meeting, May 02, 2022.
Reported Earnings • Oct 31Third quarter 2021 earnings releasedThe company reported a solid third quarter result with reduced losses, improved revenues and improved control over expenses. Third quarter 2021 results: Revenue: kr1.20m (up 459% from 3Q 2020). Net loss: kr1.82m (loss narrowed 18% from 3Q 2020).